We see further opportunities in curcumin as a therapeutic adjuvant for patients with increased NF-κB activation [59], e.g., patients with ovarian cancer [60], as well as in the prevention of recurrence of HNSCCs; curcumin also has potential as a prophylactic treatment in patients with recurrent dysplasia and positive smoking and alcohol history. Here, NFKB1 is linked to dysplasia.